We retrospectively reviewed 35 cases of adenoid cystic carcinoma that had originated in the minor salivary glands of the pa ranasal sinuses or nasa l cavity. All patients had been seen at two tertiary-care referra l centers in western New York Stat e between 1960 and 2000. Twenty patients had been treated with surgery and adju vant radiotherapy, 10 patients with surg ery alone, three with radiotherapy alon e, and two with concu rrent radiotherapy and chemot herapy. During the study, 22 patients developed recurrent disease-I I locally; three distantly; seven locally and distantly; and one locally, regionally, and distantly. At the conclusion ofthe study, 14 patients were ali ve and disease-free, and eight were alive with disease; 10 patients had died with disease, and three had died of other causes with no evidence of disease. Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity is an aggressive neopla sm that results in a high incidence of both local recurrence and distant metastasis, regardless oftreatment modality. Most cases are ultimately f atal, although long disease-f ree intervals have been observed. A combination of surgery and radiotherapy offers these patients the best chancefor disease control.
Introduction
Ade noi d cys tic ca rcinoma is an uncommon tumor that accounts for fewer than 1% of all head and neck malig-nan cies and 10% of all salivary gland neopl asm s.' :' It occ urs mo re oft en in the minor sal ivary gla nds than in the major sa livary glands .':' Th e paran asal sinus is the most co mmo n site of minor salivary gland invo lve ment. 1 .3·5 Of all malign ant paranasal sinus tumors, 5 to 15% are adenoid cystic ca rcino mas .' As with other sinus tum or s, its onset ca n be insidious." On initi al evaluat ion, most patient s have advanced disease. T he complexity of the local anatomy can make treatm ent difficult. ' Adenoi d cys tic carcinom a is a slowly progr essive and relen tless tumor th at has a tenden cy to recur locally and metastasize di st antl y.t? Recu rren ce and met astasis ca n occ ur even decades after treatment of the primary tumor .' ? This has led so me authors to co nsider adeno id cy stic ca rci no ma to be an incurabl e neoplasrn.l'r'" Th e steadfastness of thi s tumor is partially attributabl e to its ability to exte nd through subm ucosal and fibrou s tissu e plane s aro und the prim ary site and its tenden cy for perin eu ral spread along major and min or nerv es.i-" It is by exami ning the clinical character istics, treatments, and outco me s of pati ent s with ade no id cys tic ca rc ino ma of the paran asal sinuses or nasal cavi ty that we ca n de velop an und er stand ing of thi s rare an d unu su al malign an cy.
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INDICATIONS ANO USAGE
Healing ofErosiveorUlcerativeGasfroesophageal Reflux Disease (GEROI AC IPHEX' is indicated forshort-term (4toBweeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (G ERD) . for those patients who have nothealed after 8 weeks at treatment, an additional B-week course ofACIPH EX' may be considered. Maintenance 01 Healing 01 Erosive orUl cerative Gaslroesophageal RefluxDisease (GERDI ACIPHEX' isindicated formaintaining healing and reduction inrelapse rates ofheartburn symptoms inpatients with erosive orulcerative gastroesophageal refluxdisease (GERDMaintenance). Healing olOu odenal Ul cers ACIPHEX' isindicated for short-term (up tofour weeks) treatment inthe healing and symptomatic relief of duodenal ulcers. Most patients heal within fou r weeks. Tr eatment 01 Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ACI PHEX' is indicated for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison synd rome. CONTRAtNDICATIONS Rabeprazole iscontraindicated in patients with known hypersensitivity torabeprazoe, substituted benzimidazoles or toany component ofthe formulation. PRECAUTIONS General Symptomatic response totherapy with rabeprazole does notpreclude the presence ofgastric malignancy. Patients with healed GERD wer e treated for upto 40months wilh rabeprazole and monitored with serial gastric biopsies. Patients without H. pylori infection (221 of326 patients) had noclinically important pafhologicchanges in the gastric mucosa. Patients with H. pylori infection at baseline (105 of 326 patients) had mi ld or moderate inflammationinthe gastricbody or mild inflammation inthe gastricantrum . Patientswith mi ldgrades of infectionor inflammation inthe gastric body tended fachange to moderate, whereas those graded moderate at baseline tended toremainstable. Patienfswithmi ldgrades of intection or inflammation inthegastricantrum fended toremainstable. Atbaseli ne B%ofpatients had atrophy ofglands inthe gastricbody and 15%had at rophy in the gastric antrum. At endpoint, 15% of patients had at rophy of glands in the gastricbody and 11 % had atrophy in the gastric antrum. Approximately 4% of patientshad intestinal metaplasia atsome point during follow-up, but no consistent changes were seen. Information lorPatients Patients should be cautioned that ACIPH EX' delayed-release tablets shou ldbe swallowed whole. Thetablets should notbe chewed,crushed , orsplit, Orug Interactions Rabeprazoleis metabolizedbythecytoch rome P450(CYP450)drug metabolizing enzyme system.Studies inhealthy subjects have shown thatrabep razole does nothaveclinicaflysignificant inter actions with otherdrugs metabolized bythe CYP450 system, such aswarfarin an d theophylline given assingle oral doses, diazepam asa single intravenous dose, and phenytoin given as a single intravenous dose (wi th supplemental oral dosing). In vit ro incubationsemploying human liver microsomes indicated that rabeprazoleinhibited cyclosporine metabolism with an IC. of 62micromolar, aconcentrationthat isover50times higher thanthe C~inheallhyvol unteers followi ng14 days of dosing with20mgof rabeprazole. This degree of inhibition is similarto that byomeprazole at equivalent concentrations.
Rabeprazole produces sustained inhibition of gastric acid secretion. Aninteraction with compo unds which are dependent on gastric pH for absorption may occur due to themagnitUde of acid sup pression observed with rabeprazole . f or example, in normal subjects, co-administration at rabeprazote 20 mg OD resulted in an approximately 30%decrease in the bioavailabilityofketoconazoleand increases in the AUC an d C~, fordigoxin of 19%and 29%, respectively.Therefore, patients may need tobe moni toredwhen suchdrugs are taken concomitantly with rabeprazole. Co-administrationof rabeprazole and antacids prod uced no clinically relevant changes in plasma rabeprazoleconcentrations. Carcinogenesis, Mutagenesis, Impairment atfertility InaBB/I04-week carcinogenicity study inCD-I mice, rabap razole at oral doses upto100mglkg/day did not produce any increased tumor occurrence. Thehighest tested dose produced a systemic exposure to rabeprazoie (AUC) of 1,40 J lg'hr/ml which is 1.6 times thehumanexposure (plasma AUC. x =OBB Jlg'hr/ml ) atthe recommendeddose for GERD (20 mg/day). In a 104-week carcinogenicity studyin Sprague-Dawley rats, males were treated with oral doses of 5, 15,30 and 60 mglkg/day and females with 5, 15, 30, 60 and120 mglkg/day. Rabeprazole produced gastric enterochromaffin-like (ECl) cell hyperplasiain maleand femal erats and ECl cell carcinoid tumors in female rats atalldoses including thelowest tested dose. Thelowest dose (5mglkg/day) producedasystemic exposure fa rabeprazole (AUC) of about 0.1 Jlg'hr/ml which is about 0.1 times the human exposure attherecom mended dose for GERD. In male rats, notreatment related tumors were observed at doses upto 60mg/kg/day producing a rabeprazole plasma exposure (AUC) of abouf 0.2 " g·hr/ml (0.2 times the human exnosute at the recommended dose forGERD), Rabeprazolewas positive in the Ames test,the Chinese hamster ovary cell (CHOIHGPRTj torwardgene mutation test and the mouse lymphoma cell (l 517BYfTK+/-) forward gene mutation test. lts demethylated-metabolite was also positive in the Ames test. Rabeprazolewas negative inthe invitro Chinese hamster lungcellchromosome abe rration test, the in vivo mouse micronucleus test, and the in vivo andexvivo rathepatocyte unschedul ed DNA synthesis (UDS) tests. Rabeprazole at intravenous doses up to 30 mglkg/day (plasma AUCof B.B !I g·hr/ml,about 10times the human exposureat the recommended dose forGERD)was foundtohavenoeffect onfertility and reproductivepertormance ofmaleand femal erats. Pregnancy Teratogenic Effects, Pregnancy Category B:Ter atology studies have been performed inrats atinlravenous doses up to50mglkg/day (plasma AUCof 11 .8"g'hr/ml , about 13 times the human exposure atthe recommended dose for GERO) and rabbits atintravenous doses upto30mglkg/day (plasma AUCof7.3 Ilg'hr/ml , about 8 times the human exposure atthe recommended dose torGERD) and have revealed noevidence of impaired fertility or harm to the tetus due torabeprazole, Thereare, however , noadeq uate and well-tonnolled studies in pregnant women. Because animal reproductio n studies are notalways predictive of human response, this drug should be used dur ing pregnancy onlyif clearly needed. Nursing Mo thers following intravenous administration of"C-Iabeled rabeprazole to lactating rats , radioactivity in milk reached levels that were 2-to ?-fold higherthan levels in the blood. It is notknown if unmetabolized rabeprazole is excreted in human breast milk. Admi nistrationat rabeprazo le to rats in late gestationand during lactation at doses of 400mglkg/day (about 195-times the human dose based onmg/m') resulted indecreases inbody I'Jeight gainofthe pups. Since many drugs are excreted inmilk, and because of thepotentialforadverse reactions to nursing infants from rabeprazole, adecision should be made todiscontinue nursing ordiscontinue the drug, taking into account the importance ofthe drugtothe mother , Pediatric Use Thesafety andeffectiveness ofrabeprazole inpediatric patients have notbeen established. Use inWomen Duodenalulcer and erosive esophagitis healing rates inwomen are similar to those inmen. Adve rse events and laboratory test abnormalities inwomen occurred atratessimilarto those inmen. Years Resu lts Demograp hics. We identified 35 patients-17 men and 18 women, aged 18 to 82 years (mean: 57)-who had a histologic diagnosis of adenoid cystic carcinoma of the paranasal sinuse s or nasal cavity. Twenty-five patients had newly diagnosed tumors and 10 patients presented with recurrent disease. Tum or location and staging. Tumors were located in the maxillary sinu s in 19 patients , the nasal cavity in 10, and the ethmoid sinus in six. Twenty-six patie nts (74.3 %) had advanced disease at the time of our initial evaluatio n; overa ll, nine patients had stage II tumors, 10 patients were stage III, 14 were stage IV-A, and two were stage IV_C. 14 No patient had any evidence of cervic al lymph node metastasis at the initial evaluation, although two had a distant metastasis.
Overall sur vival. Overall survival rates were 65% at 5 years , 55% at 10 years , and 28% at 15 years (figure 1). Of the 13 patients who had died during the study, 10 died of disease and three died of other causes withou t evidence of disease. At the conclusion of the study , 14 patients were alive and disease-free and eight patients were alive with disease.
Mode oftherapy. Of the 35 patients , 20 had been treated with a combination of surgery and adjuvant radiotherapy, 10 patients with surgery alone , three with radiotherapy alone, and two with concurrent radiotherapy and chemotherapy (table I) . Of the 30 patients who had surgery , 26 underwent procedures that included maxillectomy, six underwent orbital exenteration, and three underwent craniofacial resec tion . All gross disease was removed in all surgically treated patients . Howev er, despite aggressive surgery , 19 of the 30 (63.3 %) had positive margins on postoperative micro scopic examination.
Metastatic disease. Overall, the lung was the most common site of metastatic dise ase (10 patients) ; other sites were bone (5), the liver (3), the brain (1), the kidney (1), the spleen (1), and the spine (1).
Patients presenting with recurrent disease. All 10 patients who presented with recurrent disea se had been previously treated with loca l excision at other institutions ; none had undergone previous radiot herapy . All came to our institut ions with local disease. We treated five of these patients with surgery plus radiation, four with surgery alone , and one with radiation alone (table 2) . Despite our treatment, new local recurrences and distant metastases were common. Seven of the 10 patients eventually died of disease. Among the three who remained alive at study 's end, two had recurrent disease and one had no evidence of disease . Patients presenting with primary tumors. Among the 25 patients who had received primary treatment at our institutions, 15 underwent surgery plus radiation, six had surgery alone, and four had radiation with or without chemotherapy (table 3) . Again, loca l recurrences and/or distant metastases were common, developing in eight of the 15 patients who underwent surgery plus radiation , in four of the six who underwent surgery alone, and in alI four who underwent radiation with or without chemotherapy. Patients in the surgery-alone group had a higher rate of loca l recurrence (4/6 [66.7 %D than did those in the surgery-plus-radiation group (5/15 [33.3 %D, but they also had a higher lO-year survival rate (67 vs 57 %; p = 0.49), according to Kaplan-Meier calcu lations (figure 2). However, none of these differences was statisti-calIy significant.
In the surgery-plus-radiation group, the eig ht patients who deve loped a loca l recurrence or distant metastasis had received a mean tota l postoperative radiation dose of 6,023 cGy, while the seven who remained disease-free received a mean dose 5,930 cGy .
Among the 25 patients who presented with primary disease, tumor site did not corre late with disease recurrence . Recurrence deve loped in four of five patients who had ethmoid tumors (80.0%), five of 12 with antral tumors (41.7 %), and three of eight with nasal cavity tumors (37.5%).
There was a trend toward an increase in the incidence of local recurrence with higher T stage, but the correlation was not statisticalIy significant. Loca l recurrence developed in two of seven patients who had a T2 tumor (28.6 %), three of seven with a T3 tumor (42.9%), and six of I I with a T4 tumor (54.5 %).
Among the 21 primary-treatment patients who underwent surgery, 12 had microscopically positive surgical margins and nine had negative margins. Loca l recurrence was more common in patients with positive margins. The percentages of combined local recurrences and distant metastases in the two groups were similar-58.3% (7/12) among patients with positive margins and 55.6% (5/9) in those wit h negative margins. However, the 10-year survival rate among patients with positive margins was only 43%, compared with 75% for those with negative margins, although the difference was not statistically significant (p = 0.13) (figure 3).
Disc uss ion
Adenoid cystic carcinoma originating in the minor salivary glands of the paranasal sinuses and nasal cavity was described in 1962 by Tauxe et al as a cancer that 
Patients in the surg ery-alone group had a higher survi val rate than did those in the surgery -plus-radiothe rapy group, althou gh at 10 years the differen ce was not stat istically significant (p = 0.49) . overall survival rates between patients who were treated with surgery plus adj uvant radiot herapy and those treated with surgery alone . Adenoid cystic carcinoma is cons idered to be a radiosensitive but not radiocurable tumor. 16.20 The rationale for administering pos toperative radiation therapy is that it treats residual microscopic disease, which is present in most patients.
Our findings are consistent with those of Spiro et aI, who wrote that postoperative irradiation most likely delays rather than prevents local recurr ence." In our patients, the mean time to the developm ent of recurrent disease was 4 yea rs and 2 months following surgery plus rad iotherapy, and 3 years and II month s following surgery alone-a difference of 3 months. Other authors have recog nized the importance of adj uvant radia tion in co ntrolli ng disease in patients with adenoid cys tic carcinoma of the head and neck. 1.8. 13.22.23 Adj uvan t radia tion following surgical resection is the main stay of treatment for patients with adenoid cystic carcinoma of the paranasal sinuses or nasal cavity.
Metastatic and recurrent disease. Unlike other head and neck cancer patients, patients with adeno id cystic carcinoma of the paranasal sinuses or nasal cavity often survive for long per iods of time with distant metastatic disease. 1, 16, 24 In our series, patients whose initial sign of recurre nce was a distant metastasis had a mea n surviva l of 2 years and 5 month s (range: 5 mo to 12 yr 6 mo). Therefore, the presence of distant metastatic disease is not a contraindication to surgical trea tme nt of the prim ary tumor in order to achieve local control. Cerv ical lymph o 70- "pursues [its] course relentlessly and maliciously.?" They adde d that "few more horrible deaths can be imag ined," as patients must endure "severe pain , paresthesia, blindness, dysph agia, deafness, dysarthria , and facial disfigurement that [occurs] over long periods and with ever increasing intens ity." Of all patients with adenoid cystic carci noma of the head and neck, those whose dise ase origi nates in the paranasal sinuses or nasal cav ity have the poorest prognosis.16.17 Thi s finding was described by Leafstedt et al in a review from the Roswell Park Cancer Institute more than 30 yea rs ago."
-
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Surgical margin s. Most of our surg ical patients (63.3%) had positive microscopic margins despite aggressive surgery, including maxillectomy, orbital exenteration, and craniofacia l resectio n. The proximity of the tumors to the skull base and the major nerve s combi ned wit h the tumor 's tendency to spread perineurally contributed to the difficul ty in obtaining surgical margins free of micro scopic disease. In our series, the primary-treatment patients who had positive margi ns experienced local recurre nces at a higher rate than did those with negat ive marg ins (41. 7 vs 22.2% ; p = 0.34).
The tendency toward local recurrence in patients with positive margins migh t be explai ned by the biologic behavior of ade noid cystic carcinoma. Howard and Lun d reported histologic evidence of an embolic pattern of perineur al sprea d in paranasal sinus adenoid cystic carcinoma." Th eir findings called into question the value of negative microscopic surgical margins in these patients. Clear margin s might corre late with better local control but not with better survival. Su pport for this theory has been expresse d by other investigators.":"
Our data suggest that despite the difficult y of achieving negative margins, doing so does appear to confer some benefit. Th erefore, we believe that aggressive surg ical treatment is indicated. However, the aggressiveness and extent of surgery should be tempered by qua lity-of-life considerations. For example, the removal of a normally functio ning eye in order to clear a micro scopic surgical margin is of questionable benefit.
Haddad et al sugge sted that positive surgical margi ns might be a reflec tion of a disea se that is more aggressive, invasive, and resistant rather than a reflection of inadequate resec tion." The possibility that positive margin s are a marker for more aggressive disease warra nts further study. 
Surgery plu s radiotherapy vs surgery alone.
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node metastasis of adenoid cystic carcinoma is rare/· l2 and no patient in our series presented with such.
Only one of our patients developed a recurrence in the neck; this patient had a particularly aggressive tumor and died within 6 months of surgery, with local recurrence, cervical node metastasis, and distant metastases to the bone and liver. The predilection of adenoid cystic carcinoma to spread hematogenously and perineurally but not lymphatically has been noted by other authors.v -"
Future study. Further investigation of the role of adjuvant chemotherapy combined with surgery and/or radiation needs to be carried out. As well, patients with adenoid cystic carcinoma of the paranasal sinuses or nasal cavity undergo treatments that are associated with very significant morbidity for a disease to which most will eventually succumb. It is therefore critical that quality-of-life issues be addressed in this patient population. 
